Predicting the stock market using Google trends
Predicting the stock market using Google trends

Predicting the stock market using Google trends

Can Google Trends help you anticipate the stock market when there are many strong models available that employ machine learning techniques? Let us investigate.

DSIJ Intelligence Article rating: 4.0

Can Google Trends help you anticipate the stock market when there are many strong models available that employ machine learning techniques? Let us investigate.

Five stocks witnessing short covering
Five stocks witnessing short covering

Five stocks witnessing short covering

Short covering refers to buying back borrowed securities in order to close out an open short position at a profit or loss.

Avalokita Pandey Article rating: 5.0

List of the stocks where sell positions are being covered in the F&O segment.

Five stocks witnessing long unwinding
Five stocks witnessing long unwinding

Five stocks witnessing long unwinding

Long unwinding refers to selling of positions or stocks owned for a longer period either to book profit or to exit it in anticipation of impending bearishness.

Avalokita Pandey Article rating: 3.2

Following are the stocks where profit booking is seen taking place in the F&O segment.

Pioneer Embroideries rallies 18.79 per cent! Heres why?
Pioneer Embroideries rallies 18.79 per cent! Heres why?

Pioneer Embroideries rallies 18.79 per cent! Heres why?

DSIJ Intelligence Article rating: 3.3

The company has already placed the order for major equipment with a Germany-based manufacturer of quality textile extrusion equipment, along with advance payments, which would enable it to secure delivery by Q3 FY23.

Cipla to launch molnupiravir in India to treat mild to moderate COVID-19 patients
Cipla to launch molnupiravir in India to treat mild to moderate COVID-19 patients

Cipla to launch molnupiravir in India to treat mild to moderate COVID-19 patients

Molnupiravir is an oral antiviral that inhibits the replication of multiple RNA viruses including SARS-CoV-2. The drug is used for the treatment of non-hospitalized patients with confirmed COVID-19 globally.

DSIJ Intelligence Article rating: 4.3

Cipla Limited announced today that it has been granted Emergency Use Authorization (EUA) permission by the Drug Controller General of India (DCGI) for the launch of Molnupiravir in the country. Cipla plans to launch Molnupiravir under the brand name Cipmolnu. Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 at high risk of developing severe disease.

RSS
First23622363236423652367236923702371Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR